Welcome to our dedicated page for Ascendis Pharma SEC filings (Ticker: ASND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ascendis Pharma A/S filings document foreign private issuer disclosures on Form 6-K, including operating and financial results, clinical and regulatory updates, capital-structure actions and security-structure changes. Recent reports cover TransCon CNP and TransCon hGH data in achondroplasia, the ordinary-share Nasdaq listing that replaced the ADS program, and the exchange of outstanding ADSs into ordinary shares.
The filing record also discloses convertible senior note redemption terms, warrant grants under the company's Articles of Association, registration-statement incorporation by reference, and equity-compensation capacity. Financial disclosures include IFRS reporting items, fair-value and derivative measurements, share capital accounts, treasury shares, and product-related revenue and royalty arrangements.
Ascendis Pharma A/S shareholder Jan Mikkelsen has filed a Form 144 notice to sell 86,860 American Depositary Shares on Nasdaq through Citigroup Global Markets. These ADS were acquired on 01/13/2026 through a restricted stock and performance stock unit compensation program, with the same date listed for acquisition and payment, and compensation noted as the nature of payment.
The notice also reports that during the past three months, Mikkelsen sold 100,000 American Depositary Shares on 12/02/2025, generating gross proceeds of 20675000.00. The filing states that the person on whose behalf the securities are to be sold represents that they do not know any material adverse information about Ascendis Pharma A/S that has not been publicly disclosed.
Ascendis Pharma A/S reports that it has provided a business and strategic roadmap update, outlining planned key corporate milestones for 2026 across its pipeline, including products such as TransCon PTH, TransCon CNP, TransCon hGH, TransCon IL-2 β/γ and TransCon aVEGF, as well as its collaboration on TransCon semaglutide.
The Board of Directors has also authorized a $120 million share repurchase program. Repurchases may be made from time to time in the open market, through privately negotiated transactions, or by other methods permitted under applicable securities laws. The company is not obligated to buy back a specific number of shares, and the program may be modified, suspended or terminated at any time without notice.
The company emphasizes that these plans and milestones are forward-looking and subject to significant risks and uncertainties, including regulatory, clinical, manufacturing, commercial, financial and geopolitical factors described in its SEC reports.
Ascendis Pharma A/S reported topline Week 52 results from COACH, its first Phase 2 trial testing once-weekly TransCon CNP and TransCon hGH combination therapy in children with achondroplasia. The company states that combination treatment showed durable growth over 52 weeks without compromising safety or tolerability, and that it also improved body proportionality and arm span in line with increased linear growth. Reported safety and tolerability were consistent with prior monotherapy experience and treatment-emergent adverse events were generally mild. TransCon CNP is under Priority Review by the U.S. FDA with a PDUFA target action date of February 28, 2026, and Ascendis has already held an end of Phase 2 meeting with the FDA regarding a planned Phase 3 pediatric achondroplasia trial.
Ascendis Pharma A/S reports that the U.S. Food and Drug Administration has classified new information it submitted on November 5, 2025 for TransCon CNP (navepegritide) as a major amendment to its New Drug Application for treating children with achondroplasia. Because of this, the FDA has extended the PDUFA target action date by three months to February 28, 2026. This change gives the FDA more time to complete its ongoing review before deciding on the application.
Ascendis Pharma A/S reported the grant of 41,220 warrants to certain employees under Appendix 1a of its Articles of Association. Each warrant entitles the holder to subscribe for one ordinary share at an exercise price of US $201.16 per share, equal to the closing price of the ADS representing the company’s ordinary shares on the grant date.
The vesting schedule provides that 25% of the warrants vest on the one-year anniversary of the grant, with the remaining 75% vesting in equal monthly installments over the subsequent 36 months, subject to continued service. Certain exit events may cause earlier vesting as provided in the Articles of Association. Following this grant, warrants to subscribe for an additional 1,753,053 shares remain available for future grant pursuant to the Articles. The Articles of Association were amended to provide for this grant and are furnished as Exhibit 1.1.
Ascendis Pharma A/S furnished unaudited Q3 2025 results via Form 6-K. Revenue rose to €213.6M (from €57.8M a year ago), driven mainly by commercial products. Q3 gross profit was €191.3M and operating profit reached €11.0M versus an operating loss last year. The quarter ended with a net loss of €61.0M and basic EPS of €(1.00).
For the nine months, revenue was €472.6M with a net loss of €194.5M and EPS of €(3.22). Product sales led results: YORVIPATH €143.1M and SKYTROFA €50.7M in Q3; North America contributed €161.1M of Q3 revenue. Cash and cash equivalents were €539.1M as of September 30, 2025. The balance sheet shows total liabilities of €1,328.8M and negative equity of €174.1M. Key financing items include convertible senior notes (€426.2M carrying amount), royalty funding liabilities (€287.8M), and derivative liabilities (€233.8M). Management states existing capital resources are expected to cover projected needs for at least twelve months from the report date.
Ascendis Pharma A/S filed a Form 6-K to provide investors with a press release reporting its financial results for the fiscal quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1 and is dated November 12, 2025.
The filing indicates that Ascendis Pharma prepares its annual reports under cover of Form 20-F and uses this Form 6-K to make its quarterly financial information available to the market.
Ascendis Pharma (ASND) reported a product update via Form 6-K. The company announced commercial availability of SKYTROFA (TransCon hGH) in broader dosing ranges in the United States. The therapy is indicated for the replacement of endogenous growth hormone in adults with growth hormone deficiency.
The report is also incorporated by reference into the company’s effective Form S-8 and Form F-3 registration statements.
Ascendis Pharma (ASND) reported a new employee equity grant. On October 14, 2025, the board granted 31,710 warrants under Appendix 1a of the Articles of Association. Each warrant entitles the holder to subscribe for one ordinary share at an exercise price of $208.71 per share, set at the ADS closing price on the grant date.
The company amended its Articles of Association to provide for this grant. Vesting follows a standard schedule: 25% on the one-year anniversary, then 1/36th monthly for the next three years, subject to continued service and earlier vesting upon certain exit events. After this grant, 1,794,273 warrants remain available for future grants pursuant to the Articles of Association.
Ascendis Pharma A/S reports that it has submitted a Marketing Authorisation Application to the European Medicines Agency for TransCon CNP (navepegritide) as a treatment for children with achondroplasia. Achondroplasia is described as a rare genetic condition that causes skeletal dysplasia and can significantly affect health, physical functioning, and quality of life.
TransCon CNP is an investigational, once-weekly prodrug of C-type natriuretic peptide designed to provide continuous exposure of active CNP throughout the body, including growth plates and skeletal muscle, with the goal of continuously inhibiting the overactive FGFR3 pathway that drives achondroplasia. The filing also notes that this 6-K is incorporated by reference into Ascendis Pharma’s existing Form S-8 and Form F-3 registration statements.